Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia

Childs, 2015, Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens, Nat Rev Drug Discov, 14, 487, 10.1038/nrd4506 Bjorkstrom, 2016, Emerging insights into natural killer cells in human peripheral tissues, Nat Rev Immunol, 16, 310, 10.1038/nri.2016.34 Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440 Ruggeri, 2007, Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value, Blood, 110, 433, 10.1182/blood-2006-07-038687 Costello, 2002, Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia, Blood, 99, 3661, 10.1182/blood.V99.10.3661 Szczepanski, 2010, Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors, Cancer Immunol Immunother, 59, 73, 10.1007/s00262-009-0724-5 Tajima, 1996, Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia, Leukemia, 10, 478 Gong, 1994, Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells, Leukemia, 8, 652 Klingemann, 1996, A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood, Biol Blood Marrow Transplant, 2, 68 Yan, 1998, Antileukemia activity of a natural killer cell line against human leukemias, Clin Cancer Res, 4, 2859 Swerdlow, 2008 Arai, 2008, Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial, Cytotherapy, 10, 625, 10.1080/14653240802301872 Tonn, 2013, Treatment of patients with advanced cancer with the natural killer cell line NK-92, Cytotherapy, 15, 1563, 10.1016/j.jcyt.2013.06.017 Cheson, 2003, Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, J Clin Oncol, 21, 4642, 10.1200/JCO.2003.04.036 Knorr, 2014, Clinical utility of natural killer cells in cancer therapy and transplantation, Semin Immunol, 26, 161, 10.1016/j.smim.2014.02.002 Miller, 2013, Therapeutic applications: natural killer cells in the clinic, Hematology, 2013, 247, 10.1182/asheducation-2013.1.247 Klingemann, 2016, Natural Killer cells for immunotherapy—advantages of the NK-92 cell line over blood NK cells, Front Immunol, 7, 91, 10.3389/fimmu.2016.00091 Suck, 2016, NK-92: an “off-the-shelf therapeutic” for adoptive natural killer cell-based cancer immunotherapy, Cancer Immunol Immunother, 65, 485, 10.1007/s00262-015-1761-x Bachanova, 2014, Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein, Blood, 123, 3855, 10.1182/blood-2013-10-532531 Curti, 2011, Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients, Blood, 118, 3273, 10.1182/blood-2011-01-329508 Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, 105, 3051, 10.1182/blood-2004-07-2974 Rubnitz, 2010, NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia, J Clin Oncol, 28, 955, 10.1200/JCO.2009.24.4590 Nannmark, 2000, Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells, In Vivo, 14, 651 Pegram, 2010, Characterizing the anti-tumor function of adoptively transferred NK cells in vivo, Cancer Immunol Immunother, 59, 1235, 10.1007/s00262-010-0848-7 Boyiadzis, 2016, Circulating exosomes carrying an immunosuppressive cargo interfere with adoptive cell therapy in acute myeloid leukemia, Blood, 128, 1609, 10.1182/blood.V128.22.1609.1609 Boyiadzis, 2008, Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels, Biol Blood Marrow Transplant, 14, 290, 10.1016/j.bbmt.2007.12.490 Chik, 2003, Elevated serum interleukin-15 level in acute graft-versus-host disease after hematopoietic cell transplantation, J Pediatr Hematol Oncol, 25, 960, 10.1097/00043426-200312000-00011